# Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

> **NCT01753076** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 304 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Ozanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01753076
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-20
- **Primary completion:** 2015-01-22
- **Final completion:** 2015-01-22
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753076, "Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01753076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*